reports
- Maria Vara
ONWARD: Expanding BCI clinical evidence with 5th implant milestone
This morning, ONWARD announced two additional successful implants of its ARC-BCI system in SCI patients, bringing the total to five as part of ongoing clinical feasibility studies. The latest cases involved a 48-year-old man (upper-limb SCI, injury in 2024) and a 37-year-old woman (lower-limb SCI,
- Maria Vara
ONWARD: BCI in action – Lausanne visit takeaways
Last week, we had the opportunity to visit ONWARD’s headquarters in Lausanne, Switzerland, and tour the NeuroRestore lab, where much of its clinical innovation takes place. The broader ecosystem—anchored by EPFL’s engineering strength and CHUV’s clinical leadership—offers a clear strategic edge as
- Maria Vara
ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders
Yesterday, we hosted an exclusive fireside chat at our Paris HQ with ONWARD's co-founders, Dr. Grégoire Courtine and Dr. Jocelyne Bloch, accompanied by institutional investors, to learn about the professional endeavours that led them to jump from researchers to entrepreneurs, with a special deep-di
- Maria Vara
ONWARD: Opening the door to US investors with OTCQX ADR listing
ONWARD has taken a strategic step toward expanding its US investor base by launching a sponsored Level 1 ADR program, with its shares to trade on the OTCQX Best Market under the ticker ONWRY, with a one-to-one ratio with respect to the company's ordinary shares. Partnering with BNY Mellon as deposi
- Maria Vara
ONWARD: FY24 Update – Commercial inflection begins, near-term mileston...
This morning, ONWARD shared FY 2024 business update highlighting a highly comprehensive list of achievements across clinical development, IP and corporate actions, while posting the first commercial sales of ARC EX following its de Novo FDA approval on 20th December. As communicated previously, two
- Maria Vara
ONWARD Medical: First ARC‑IM Lumbar Lead implanted
This morning, ONWARD announced the first implantation of the proprietary ARC-IM Lumbar Lead designed for the lumbar region, which aims to effectively deliver ARC Therapy to potentially enable motor functions linked to the lower limbs, including standing, stepping and overall mobility. The implantat
- Maria Vara
ONWARD Medical: more grants are coming in to advance Parkinson's disea...
Along with the imminent kick-off of the US IDE study for ARC-IM targeting Blood Pressure (BP) in the SCI population, ONWARD Medical is advancing its ARC-IM pipeline in Parkinson’s disease within a financially de-risked setting launching two early feasibility studies to address i) mobility challenge
- Maria Vara
ONWARD: 1-year ARC-EX Therapy unlocks additional recovery in SCI
This morning, ONWARD Medical shared a publication detailing supportive results from an independent, investigator-sponsored Pathfinder2 study, further building the clinical evidence for ARC-EX's therapeutic potential to restore function in SCI patients. While the Up‑LIFT study demonstrated groundbre
- Maria Vara
ONWARD Medical: Expanding access of ARC-EX via VA and GSA platforms
ONWARD Medical continues to advance its phased commercial strategy with the announcement that its ARC-EX system is now commercially available through the US Department of Veterans Affairs (VA) Federal Supply Schedule and GSA Advantage platforms, a crucial milestone in addressing the sizeable chroni
- Maria Vara
ONWARD Medical: US commercial launch sparks momentum, driving 23% YTD ...
ONWARD's stock has surged by ~+23% YTD, marking its highest level in recent memory. This rally reflects the company’s latest milestone: its first commercial sales in the US, announced last week (here). The news follows the de novo clearance of the ARC-EX System in December 2024 (read our note here)
- Maria Vara
ONWARD Medical: ARC-EX hits market with first commercial sales
This morning, ONWARD announced it had achieved a significant milestone with the first commercial sales of its ARC-EX System in the US, purchased by UW Medicine and Next Steps Chicago. The sales come shortly after the device received the FDA de novo classification in December 2024, establishing ARC-
- Maria Vara
ONWARD marks commercial breakthrough with FDA green light for ARC-EX
Post-market yesterday, ONWARD announced it has received De Novo FDA approval for ARC-EX Therapy to improve upper limb mobility in SCI patients, meeting both the timeline and positive clearance expectations. This milestone marks the first product launch from ONWARD’s enriched pipeline, aimed at addr
- Maria Vara
ONWARD Medical secures EcoVadis silver medal for sustainability leader...
ONWARD Medical announced it has earned a silver medal from EcoVadis, ranking in the top 15% of over 130k companies globally for corporate sustainability. This recognition reflects the company’s dedication to environmental responsibility, ethical labour practices, and sustainable procurement, which
- Maria Vara
ONWARD Medical: steady execution in Q3 2024
This morning, ONWARD shared a Q3 business update highlighting major YTD achievements across clinical development, IP and corporate actions. While the update contained no surprises, we appreciate the highly productive quarter, during which the company steadily delivered on all three fronts aligned w
- Maria Vara
ONWARD Medical: EIC grant expands ARC-BCI development to subcortical s...
This morning, ONWARD Medical announced that it had secured a significant grant from the European Innovation Council (EIC) to investigate and develop ARC-BCI Therapy aimed at restoring upper limb function in patients with subcortical stroke. While SCI-related movement disorders remain the company’s
- Maria Vara
ONWARD Medical: ARC-EX recognised as one of TIME's Best Inventions of ...
ONWARD Medical's investigational ARC-EX System was named one of TIME's Best Inventions of 2024, spotlighting its potential to improve life for SCI. Recognised for originality, efficacy, ambition, and impact, the ARC-EX System enables SCI patients to regain hand and arm function, as evidenced by the
- Maria Vara
ONWARD Medical: successful EUR50m upsized raise with Ottobock as corne...
ONWARD Medical successfully secured a capital raise of EUR50m in total gross proceeds through an upsized bookbuild offering via a private placement. Ottobock contributed EUR22.5m as a strategic cornerstone investor, with the potential for synergistic value creation in both the near and long term. T
- Maria Vara
ONWARD Medical: bolsters leadership ahead of ARC-EX launch
This morning, ONWARD Medical announced that Rob ten Hoedt, former EVP at Medtronic and Chairman of MedTech Europe, will join its Board of Directors and take over as Chairman by YE, following the planned retirement of Jan Ohrstrom after 8 years of service. Ten Hoedt's experience at Medtronic and lea
- Maria Vara
ONWARD Medical: officially becomes a BCI company
This morning, ONWARD announced that it has entered an exclusive R&D and commercialisation licence agreement with its BCI partner CEA-CLINATEC concerning the WIMAGINE BCI as an integral part of ONWARD's ARC-BCI System. While the company focuses on bringing ARC-EX to market by YE 2024, we see thi
- Maria Vara
ONWARD Medical: listing on Euronext Paris tomorrow, non-dilutive offer...
On Friday post-market, ONWARD Medical announced that its shares will begin trading on Euronext Paris as of tomorrow 24th September, complementing its existing listings on Euronext Brussels and Amsterdam. As a non-dilutive offering, we view this as a positive move to enhance access for French retail
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.